Rethinking clinical trials for cytostatic drugs.
The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design--survival as an end point and simultaneous combination with cytotoxic chemotherapy--and indicate possible alternatives.